Overall, pre-clinical studies suggested that the beneficial effects of GLP-1 agonists in osteoarthritis were primarily mediated through inhibiting the activation of the NF-κB pathway [21,22,25]. This evidence concerns the gene NFKB1 and osteoarthritis.